Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shaji Kumar

Showing results (181-190 of 515) with videos related to

Pageof 52
Sort By:
European Journal of Haematology|February 9, 2017
Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-regression analysisMaria Mainou, Anastasia-Vasiliki Madenidou, Aris Liakos, et al.
Blood|April 14, 2005
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myelomaNoopur Raje, Shaji Kumar, Teru Hideshima, et al.
Journal of Primary Care & Community Health|July 25, 2024
Writing Groups for Healthcare Professionals in Academic MedicineIvana T Croghan, Shaji Kumar, Sagar B Dugani, et al.
Mayo Clinic Proceedings|February 5, 2019
Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015Robert A Kyle, Dirk R Larson, Paul J Kurtin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 20, 2010
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell TransplantationSteven Z Pavletic, Shaji Kumar, Mohamad Mohty, et al.
European Journal of Haematology|May 8, 2013
Differences in the distribution of cytogenetic subtypes between multiple myeloma patients with and without a family history of monoclonal gammopathy and multiple myelomaAlexandra J Greenberg, Margot Cousin, Shaji Kumar, et al.
Leukemia & Lymphoma|November 12, 2013
Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignanciesTariq I Mughal, Saulius Girnius, Steven T Rosen, et al.
Leukemia Research|August 2, 2006
Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progressionMichael Kline, Kathleen Donovan, Linda Wellik, et al.
Blood|June 26, 2004
VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosisSteven Le Gouill, Klaus Podar, Martine Amiot, et al.
American Journal of Hematology|December 23, 2011
Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycinVijay Ramakrishnan, Michael Timm, Jessica L Haug, et al.
Pageof 52

Showing results (181-190 of 515) with videos related to

Sort By:
Pageof 52
European Journal of Haematology|February 9, 2017
Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-regression analysisMaria Mainou, Anastasia-Vasiliki Madenidou, Aris Liakos, et al.
Blood|April 14, 2005
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myelomaNoopur Raje, Shaji Kumar, Teru Hideshima, et al.
Journal of Primary Care & Community Health|July 25, 2024
Writing Groups for Healthcare Professionals in Academic MedicineIvana T Croghan, Shaji Kumar, Sagar B Dugani, et al.
Mayo Clinic Proceedings|February 5, 2019
Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015Robert A Kyle, Dirk R Larson, Paul J Kurtin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 20, 2010
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell TransplantationSteven Z Pavletic, Shaji Kumar, Mohamad Mohty, et al.
European Journal of Haematology|May 8, 2013
Differences in the distribution of cytogenetic subtypes between multiple myeloma patients with and without a family history of monoclonal gammopathy and multiple myelomaAlexandra J Greenberg, Margot Cousin, Shaji Kumar, et al.
Leukemia & Lymphoma|November 12, 2013
Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignanciesTariq I Mughal, Saulius Girnius, Steven T Rosen, et al.
Leukemia Research|August 2, 2006
Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progressionMichael Kline, Kathleen Donovan, Linda Wellik, et al.
Blood|June 26, 2004
VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosisSteven Le Gouill, Klaus Podar, Martine Amiot, et al.
American Journal of Hematology|December 23, 2011
Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycinVijay Ramakrishnan, Michael Timm, Jessica L Haug, et al.
Pageof 52